1. Olaparib@human serum albumin nanoparticles as sustained drug-releasing tumour-targeting nanomedicine to inhibit growth and metastasis in the mouse model of triple-negative breast cancer
    Nageswara Rao Vysyaraju et al, 2022, Journal of Drug Targeting CrossRef
  2. Inhibitors of PARP-1 exert inhibitory effects on the biological characteristics of hepatocellular carcinoma cells in vitro
    Xiaorong Mao et al, 2017, Molecular Medicine Reports CrossRef
  3. Generation and characterization of a cell line from an intraductal tubulopapillary neoplasm of the pancreas
    Matthäus Felsenstein et al, 2020, Laboratory Investigation CrossRef
  4. PARP Inhibitors in Pancreatic Cancer
    Timothy J. Brown et al, 2021, The Cancer Journal CrossRef
  5. Ultrasensitive electrochemical detection of poly (ADP-ribose) polymerase-1 via polyaniline deposition
    Yong Liu et al, 2018, Talanta CrossRef
  6. PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine
    Francisco Quiñonero et al, 2022, Biomedicine & Pharmacotherapy CrossRef
  7. Pre-activation of autophagy impacts response to olaparib in prostate cancer cells
    Maxime Cahuzac et al, 2022, Communications Biology CrossRef